Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase
Paul Harmatz(Unknown), Celeste Decker(BioMarin (United States)), Ida Vanessa Döederlein Schwartz(Services Hospital), Maurizio Scarpa(Unknown), David Ketteridge(Women's and Children's Hospital), Robert D. Steiner(University of Wisconsin–Madison), Nathalie Guffon(Hôpital Edouard Herriot), Elisa Leão Teles(Hospital de São João), Barbara Plecko(Graz University Hospital), Laila Arash(University of Padua), Roberto Giugliani(Universidade Federal do Rio Grande do Sul), Clara Sá-Miranda(Universidade do Porto), Michael Beck(Eastern Illinois University), John J. Hopwood(Women's and Children's Hospital), Stuart J. Swiedler(Hospital de São João), J. E. Wraith(Boston Children's Hospital), Zi-Fan Yu(Statistics Collaborative), Chester B. Whitley(University of Minnesota), Paige Kaplan(Children's Hospital of Philadelphia)
Cited by 216
Related Papers
Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene
|Nature Genetics|1999|571
Agalsidase-Beta Therapy for Advanced Fabry Disease
|Annals of Internal Medicine|2007|565
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|522
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364